Corrigendum to "Modern management of epilepsy: A practical approach" [Epilepsy Behav 12 (2008) 501-539] (DOI:10.1016/j.yebeh.2008.06.010);Diurnal lamotrigine plasma level fluctuations: clinical significance and indication of shorter half-life with chronic administration

Epilepsy and Behavior

Volumn 13, Issue 3, 2008, Pages 470-473

  Nielsen, Kirsten A ^a   Dahl, Marit ^a   Tømmerup, Erling ^a   Hansen, Bjarke á Rogvi ^b   Erdal, Jesper ^b   Wolf, Peter ^a,b  

^a DANISH EPILEPSY CENTRE   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Breakthrough seizure; Daily fluctuations; Lamotrigine; Therapeutic drug monitoring

Indexed keywords

CLOBAZAM; ETHOSUXIMIDE; ETIRACETAM; LAMOTRIGINE; PHENOBARBITAL; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADULT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MONITORING; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; SEIZURE;

EID: 50849136813     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2008.06.018     Document Type: Erratum

References (17)

1. Mayer Th., May T.W., Altenmüller D.-.M., Sandmann M., and Wolf P. Clinical problems with generic antiepileptic drugs: comparison of sustained-release formulations of carbamazepine. Clin Drug Invest 18 (1999) 17-26
2. Wolf P., May T., Tiska G., and Schreiber G. Steady state concentrations and diurnal fluctuations of carbamazepine in patients with different slow release formulations. Arzneimittelforschung 42 (1992) 284-288
3. Søndergaard Khinchi M., Nielsen K.A., Dahl M., and Wolf P. Lamotrigine therapeutic thresholds. Seizure 17 (2008) 391-395
4. Garnett W.R. Lamotrigine, interaction with other drugs. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic drugs. 5th ed. (2002), Lippincott, Williams & Wilkins, Philadelphia 380-388
5. Ramsay E.R., Pellock J.M., Garnett W.R., et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 10 (1991) 191-200
6. May T.W., Rambeck B., and Jürgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit 18 (1996) 523-531
7. Jann M.W., Hon Y.Y., Shamsi S.A., Zheng J., Awad E.A., and Spratlin V. Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. Pharmacotherapy 26 (2006) 627-633
8. Sidhu J., Job S., Bullmann J., et al. Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. Br J Clin Pharmacol 61 (2006) 420-426
9. Theis J.G., Sidhu J., Palmer J., Job S., Bullmann J., and Archer J. Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine. Neuropsychopharmacology 30 (2005) 2269-2274
10. Doose D.R., Brodie M.J., Wilson E.A., et al. Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia 44 (2003) 917-922
11. Tompson D.J., Ali I., Oliver-Willwong R., et al. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy: the COMPASS Study. Epilepsia 49 (2008) 410-417
12. Nielsen K.A., Dahl M., Tømmerup E., and Wolf P. Comparative daily profiles with different preparations of lamotrigine: a pilot investigation. Epilepsy Behav 13 (2008) 127-130
13. http://www.laegemiddelstyrelsen.dk/1024/visL5Artikel.asp?artikelID=10139.
14. Johannessen S.I., and Tomson T. Pharmacokinetic variability of newer antiepileptic drugs. Clin Pharmacokinet 45 (2006) 1061-1075
15. Specht U., Elsner H., May T.W., Schichimawski B., and Thorbecke R. Postictal serum levels of antiepileptic drugs for detection of non-compliance. Epilepsy Behav 4 (2003) 487-495
16. Hussein Z., and Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 43 (1997) 457-465
17. Almeida A.M., Falcão A.C., Sales F., Baldeiras I., Rocha M.J., and Caramona M.M. Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. Eur J Clin Pharmacol 62 (2006) 737-742